You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Thoroughly updated to reflect major advances in the field of immuno-oncology, this second edition of Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), remains the definitive resource for information on tumor immunology and cancer immunotherapy treatments. An essential reference for both novice and experienced cancer researchers, oncologists, and related practitioners alike, the book not only guides readers through the fundamental scientific principles of the field all the way to translational and practical clinical applications for treating and managing oncologic disease, but also provides a comprehensive understanding of the regulatory proces...
“Drs. Butterfield, Kaufman and Marincola on behalf of the SITC have created a comprehensive must-have resource covering the basic and translational science behind approved and investigational immune therapies, and disease-by-disease clinical application of the therapies, written by leaders in the field. The textbook will be highly valuable reading for those just entering the field and for experienced scientists and clinicians looking to expand their knowledge base.” —Mario Sznol, MD, Professor of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut “Given the important and exciting advances in cancer immunotherapy, it is not surprising that there is no dearth ...
Cancer is fundamentally a disease of abnormal cell proliferation: Cancer cells multiply when and where they should not. This proliferation entails escape from normal bounds imposed by the tissue environment, the internal biology of the cell (DNA damage, chromosomal imbalances, disorganized mitotic spindles), and the proliferative history of the cell (normal generational times). Some of the key oncogenic events in cancer directly perturb proteins that regulate progression through the cell division cycle, others alter cell cycle progression indirectly, through effects on signaling pathway that impinge on the cell cycle. This biology is fundamentally important in cancer therapy. Many of the workhorse treatments for cancer rely on killing proliferating cells. Furthermore, there is growing recognition that stem cell-transit amplifying cell hierarchies may persist or be generated during tumorigenesis, generating important functional heterogeneity in cell cycle control among tumor cells, with far-reaching scientific and clinical implications. This volume outlines major cell cycle perturbations that drive tumorigenesis and considers the prospects for using such knowledge in cancer therapy.
First Prize, BMA Medical Book Awards 2013Breast cancers are now detected earlier and are thus more likely to be confined to the breast itself and regional nodes. Many of these tumours will have minimal proclivity for hematogenous dissemination and formation of micrometastases. On the other hand, some patients have micrometastatic diseases which can
None
This book will be a comprehensive study of the lymphatic system and its immunological role. It will begin with lymphatic capillaries, their origin and development. It will treat lymph circulation, in general, with a special emphasis on lymph circulation in parenchymal organs. The next section will address lymph nodes, subcortical circulation and the conduit system. It will discuss organs with no lymphatic system, such as the brain. Finally, it will cover lymph composition and cells in the lymph. While primarily basic research, the volume will touch upon elements of the clinical, as well, broadening its scope and appeal.
The ultimate guide to caring for and communicating with patients suffering with hereditary cancer syndromes Providing the essential tools needed to understand clinical cancer genetics, Cancer Genetics: A Clinical Approach builds your mastery of differential diagnosis formulation, all the available genetic testing options at your disposal, interpreting results logically and accurately, and educating patients and their families about effective cancer prevention methods. This unparalleled resource walks you through the process of effectively and thoughtfully counseling patients—from pre-test counseling and relaying test results to navigating the legal implications of hereditary conditions and coping with the resulting psychological challenges. Cancer Genetics: A Clinical Approach is ideal for both specialized cancer genetics clinics or any healthcare professional seeking to improve their skills in identifying patients with possible hereditary cancer syndromes and recognizing which ones should be referred to a high-risk/clinical genetics specialty program.
Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for...
Many cancer patients are diagnosed at a stage in which the cancer is too far advanced to be cured, and most cancer treatments are effective in only a minority of patients undergoing therapy. Thus, there is tremendous opportunity to improve the outcome for people with cancer by enhancing detection and treatment approaches. Biomarkers will be instrumental in making that transition. Advances in biotechnology and genomics have given scientists new hope that biomarkers can be used to improve cancer screening and detection, to improve the drug development process, and to enhance the effectiveness and safety of cancer care by allowing physicians to tailor treatment for individual patients—an approach known as personalized medicine. However, progress overall has been slow, despite considerable effort and investment, and there are still many challenges and obstacles to overcome before this paradigm shift in oncology can become a reality.
Clostridium difficile has been recognized as the cause of a broad spectrum of enteric disease ranging from mild antibiotic-associated diarrhea to pseudomembranous colitis. This volume gives new insights into the microbiology, diagnostics and epidemiology of Clostridium difficile and describes recent strategies in treatment of diseases caused by this agent. Main parts of the volume are devoted to Clostridium difficile toxins A and B which are the major virulence factors. The molecular biology, biochemistry, pharmacology and cell biology of these toxins which are the prototypes of a new family of large clostridial cytotoxins is described in great detail. Clostridium difficile toxins act as glucosyltransferases to inactivate small GTP-binding proteins of the Rho family which are involved in regulation of the actin cytoskeleton, cell adhesion and various signaling processes.